Medigene AG
MDGEF · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $6,034 | $31,247 | $10,463 | $8,002 |
| % Growth | -80.7% | 198.6% | 30.8% | – |
| Cost of Goods Sold | $1,643 | $23,835 | $4,788 | $7,764 |
| Gross Profit | $4,391 | $7,412 | $5,675 | $238 |
| % Margin | 72.8% | 23.7% | 54.2% | 3% |
| R&D Expenses | $11,545 | $7,179 | $9,950 | $18,551 |
| G&A Expenses | $9,316 | $7,692 | $2,824 | $3,687 |
| SG&A Expenses | $9,336 | $9,885 | $2,940 | $8,885 |
| Sales & Mktg Exp. | $20 | $2,193 | $116 | $91 |
| Other Operating Expenses | -$341 | -$532 | $3,296 | $0 |
| Operating Expenses | $20,540 | $16,532 | $16,186 | $27,436 |
| Operating Income | -$16,149 | -$9,120 | -$10,511 | -$27,198 |
| % Margin | -267.6% | -29.2% | -100.5% | -339.9% |
| Other Income/Exp. Net | -$443 | -$254 | $228 | $261 |
| Pre-Tax Income | -$16,592 | -$9,374 | -$10,283 | -$28,403 |
| Tax Expense | -$415 | -$1,044 | -$300 | $472 |
| Net Income | -$16,177 | -$8,330 | -$9,983 | -$28,875 |
| % Margin | -268.1% | -26.7% | -95.4% | -360.8% |
| EPS | -1.32 | -0.64 | -0.77 | -2.23 |
| % Growth | -106.3% | 16.9% | 65.5% | – |
| EPS Diluted | -1.32 | -0.64 | -0.77 | -2.23 |
| Weighted Avg Shares Out | 12,281 | 12,933 | 12,933 | 12,933 |
| Weighted Avg Shares Out Dil | 12,281 | 12,933 | 12,933 | 12,933 |
| Supplemental Information | – | – | – | – |
| Interest Income | $135 | $29 | $19 | $63 |
| Interest Expense | $544 | $634 | $344 | $399 |
| Depreciation & Amortization | $603 | $21,852 | $3,428 | $6,472 |
| EBITDA | -$15,445 | $13,112 | -$6,511 | -$21,532 |
| % Margin | -256% | 42% | -62.2% | -269.1% |